Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
Akeso keeps cadonilimab in China
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
MacroGenics cuts down its Tamarack
Vobra-duo is discontinued at long last.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Is this the end for MacroGenics’ vobra-duo?
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
MacroGenics gets that sinking feeling
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
